Jane Myers

852 total citations
15 papers, 614 citations indexed

About

Jane Myers is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Jane Myers has authored 15 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Neurology. Recurrent topics in Jane Myers's work include Lymphoma Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (9 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Jane Myers is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (9 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Jane Myers collaborates with scholars based in United States. Jane Myers's co-authors include David J. Straus, Joachim Yahalom, B Clarkson, James F. Caravelli, Jeffrey J. Gaynor, Andrew D. Zelenetz, Craig H. Moskowitz, Jing Qin, Ariela Noy and Carol S. Portlock and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jane Myers

15 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Myers United States 10 554 252 249 212 138 15 614
CN Coleman United States 5 449 0.8× 186 0.7× 177 0.7× 160 0.8× 93 0.7× 7 544
J.H. Meerwaldt Netherlands 10 691 1.2× 322 1.3× 343 1.4× 173 0.8× 181 1.3× 15 869
N. Dupouy France 10 388 0.7× 344 1.4× 216 0.9× 141 0.7× 74 0.5× 13 707
Scot Sorensen United States 9 472 0.9× 150 0.6× 260 1.0× 179 0.8× 169 1.2× 10 602
Delia Rota Scalabrini Italy 11 447 0.8× 134 0.5× 290 1.2× 188 0.9× 97 0.7× 25 600
D L Longo United States 6 306 0.6× 390 1.5× 292 1.2× 197 0.9× 69 0.5× 6 743
D F Moravec United States 6 466 0.8× 97 0.4× 237 1.0× 171 0.8× 143 1.0× 8 516
J O Armitage United States 7 493 0.9× 103 0.4× 298 1.2× 134 0.6× 214 1.6× 9 609
P. Gobbi Italy 12 329 0.6× 99 0.4× 195 0.8× 104 0.5× 96 0.7× 20 469
Patrizia Albertini Italy 12 576 1.0× 140 0.6× 260 1.0× 213 1.0× 150 1.1× 17 714

Countries citing papers authored by Jane Myers

Since Specialization
Citations

This map shows the geographic impact of Jane Myers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Myers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Myers more than expected).

Fields of papers citing papers by Jane Myers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Myers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Myers. The network helps show where Jane Myers may publish in the future.

Co-authorship network of co-authors of Jane Myers

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Myers. A scholar is included among the top collaborators of Jane Myers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Myers. Jane Myers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Papadimitrakopoulou, V., John V. Heymach, Stephen Jay Frank, et al.. (2011). Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 29(15_suppl). 5510–5510. 4 indexed citations
2.
Portlock, C., Jing Qin, Nancy Roistacher, et al.. (2004). The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Annals of Oncology. 15(10). 1495–1503. 13 indexed citations
3.
4.
Younes, Anas, Fernando Cabanillas, Peter W. McLaughlin, et al.. (1996). Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Annals of Oncology. 7(10). 1083–1085. 6 indexed citations
5.
6.
Straus, David J., Joachim Yahalom, Jeffrey J. Gaynor, et al.. (1992). Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease. Cancer. 69(4). 1052–1060. 23 indexed citations
7.
Yahalom, Joachim, Jin‐Sook Ryu, David J. Straus, et al.. (1991). Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations.. Journal of Clinical Oncology. 9(12). 2193–2201. 67 indexed citations
8.
Straus, David J., Jeffrey J. Gaynor, Jane Myers, et al.. (1990). Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.. Journal of Clinical Oncology. 8(7). 1173–1186. 125 indexed citations
9.
Straus, David J., Jeffrey J. Gaynor, Jane Myers, et al.. (1989). Results and Prognostic Factors Following Optimal Treatment of Advanced Hodgkin’s Disease. Recent results in cancer research. 117. 191–196. 1 indexed citations
10.
Koziner, Benjamín, Jane Myers, Constance Cirrincione, et al.. (1986). Treatment of stages I and II hodgkin's disease with three different therapeutic modalities. The American Journal of Medicine. 80(6). 1067–1078. 28 indexed citations
11.
Straus, David J., Jane Myers, Burton J. Lee, et al.. (1984). Treatment of advanced hodgkin's disease with chemotherapy and irradiation. The American Journal of Medicine. 76(2). 270–278. 35 indexed citations
12.
Myers, Jane, et al.. (1983). Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Cancer Chemotherapy and Pharmacology. 11(2). 80–5. 26 indexed citations
13.
Cw, Young, Jane Myers, Sharon Passe, et al.. (1982). Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease.. PubMed. 66(4). 907–14. 7 indexed citations
14.
Hoff, Daniel D. Von, D S Alberts, Douglas E. Mattox, et al.. (1981). Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer.. PubMed. 4(2). 215–8. 5 indexed citations
15.
Straus, David J., Jane Myers, Sharon Passe, et al.. (1980). The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease. A follow-up report. Cancer. 46(2). 233–240. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by CN Coleman Breakdown of academic impact, for papers by J.H. Meerwaldt Breakdown of academic impact, for papers by N. Dupouy Breakdown of academic impact, for papers by Scot Sorensen Breakdown of academic impact, for papers by Delia Rota Scalabrini Breakdown of academic impact, for papers by D L Longo Breakdown of academic impact, for papers by D F Moravec Breakdown of academic impact, for papers by J O Armitage Breakdown of academic impact, for papers by P. Gobbi Breakdown of academic impact, for papers by Patrizia Albertini
Rankless by CCL
2026